Generic Name and Formulations:
Mexiletine HCl 150mg, 200mg, 250mg; caps.
Various generic manufacturers
Indications for Mexiletine:
Documented life-threatening ventricular arrhythmias.
Take with food or antacid. Initially 200mg every 8hrs. Adjust dose if needed at not less than 2–3 day intervals in 50–100mg increments. Usual dose: 200–300mg every 8hrs; max 1.2g/day. If arrhythmia is controlled by ≤300mg every 8hrs, may try dividing same daily dose every 12hrs; max 450mg every 12hrs. See literature for information on rapid induction and changing from other antiarrhythmics.
Cardiogenic shock. 2nd- or 3rd- degree AV block unless paced.
Hepatic impairment. Severe heart failure. Sinus node dysfunction or intraventricular conduction defects. Hypotension. Epilepsy. Monitor ECG, blood and liver function. Pregnancy (Cat.C). Nursing mothers: not recommended.
May potentiate other antiarrhythmics, theophylline. Monitor control if used with hepatic enzyme-inducing drugs. Avoid drugs or diets that alter urinary pH.
Class IB antiarrhythmic.
GI upset, dizziness, tremor, nervousness, ataxia, chest pain, blurred vision, exacerbated arrhythmias, hepatotoxicity.
Formerly known under the brand name Mexitil.
Endocrinology Advisor Articles
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
- Achieving Glycemic Control in T2D After Basal Insulin Initiation
- Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up
- Effects of the Two Types of Anorexia Nervosa on Bone Metabolism
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Risk for Iodine Deficiency and Hypothyroidism High in Children on Parenteral Nutrition
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- Glycemic Control Variations for Children, Adolescents With T1D in High-Income Countries
- Late-Life Mobility Limitations Linked to Obesity After Arthroplasty for OA in Women
- Fracture Risk Should Be Monitored in Bisphosphonate Drug Holiday
- Provider Counseling for Weight Loss Up for Arthritis, Overweight